Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination

Inclusion Criteria: * Patients undergoing myeloablative or non-myeloablative allogeneic transplantation from an HLA (A, B and DR) identical or 1-3 antigen mismatched family or unrelated donor. * Transplant performed for any type of non-malignant condition or haematological malignancy including but not limited to acute and chronic leukaemia, myelodysplasia, non Hodkgins and Hodgkin lymphoma or myeloma. * Recipients of peripheral blood or bone marrow stem cells. * Adequate hepatic and renal function (\< 3 x upper limit of normal for AST (SGOT), ALT (SGPT), \< 2 x upper limit of normal for total bilirubin, serum creatinine). * Estimated life expectancy of at least 6 months. * Patient (or legal representative) has given informed consent Exclusion Criteria: * Use of anti-lymphocyte globulin (ALG, ATG, Campath or other broad spectrum lymphocyte antibody) given in the 4 weeks immediately prior to infusion or planned within 4 weeks after infusion. * Grade II or greater graft versus host disease within 1 week prior to infusion. * Prednisone or methylprednisone at a dose of \> 1 mg/kg (or equivalent in other steroid preparations) administered within 72 hours prior to cell infusion. * Allergies to eggs or components of the Fluvax or Varivax vaccines. * Privately insured in or outpatients